Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Heros Health vs Hims & Hers

By GLP-1 ScorecardUpdated

Heros Health
Site position #214

Lower grade

Hims & Hers
Site position #56

Higher grade

Score comparison

Hims & Hers has the higher recorded score — 75.6/100 to 66.3/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHims & Hers +22
60
82
Dose & formulationHims & Hers +14
64
78
Clinical oversightHeros Health +32
87
55
Labs & monitoringHims & Hers +26
54
80
FulfillmentHims & Hers +8
76
84
Contract termsHims & Hers +31
49
80
Heros Health · top barHims & Hers · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricHeros HealthHims & Hers
WeighScore66.3/10075.6/100
GradeCC
Site position#214#56
Semaglutide$199/mo (compounded)$199/mo
Tirzepatide$199/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Heros Health

Site position #214 · C

Strengths

  • Compounded semaglutide and tirzepatide on a flat program price, not tiered by dose
  • Transparent pricing: $149 first month, then $199/mo (or $165/mo on the 3-month plan)
  • 90-day money-back guarantee on GLP-1 treatment
  • Dose adjustments at weeks 2, 4, and 8 included at no extra cost
  • Named board-certified physicians (Dr. Amber Patel, Dr. Scott Sanderson, Dr. Scott Nass)

What to consider

  • Compounded GLP-1s are not FDA-approved finished products
  • Specific 503A pharmacy partner is not named publicly
  • State coverage is stated inconsistently on the site (claims both 50 and 46 states)
  • No insurance billing — cash-pay only
Hims & Hers

Site position #56 · C

FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

What to consider

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard